Biomarkers Clinical Trial
Official title:
Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients With High-grade Cervical Intraepithelial Lesions Treated With Imiquimod
The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.
INTRODUCTION: High-grade intraepithelial lesions (CIN 2/3) are considered precursor lesions of cervical cancer, and its treatment involves destructive or excisional methods. Some studies have proven the efficacy of the immunomodulator imiquimod as a topical treatment for CIN 2/3 lesions. Imiquimod activates the innate immune response through dendritic cells, monocytes and macrophages, in addition to modulating the response pattern of T lymphocytes. Thus, the characterization of the immune response in the treatment with imiquimod in lesions caused by oncogenic HPV, may benefit women in a way that it is possible to measure the response of each patient, improving the understanding of its mechanism of action, directly impacting the efficacy and adverse events. caused by the drug. OBJECTIVES: To identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. MATERIALS AND METHODS: It will be included 90 patients, 60 with high-risk HPV, diagnosed with CIN 3 and 30 patients with negative cytology and HPV. Patients will be divided into 3 groups: 1) patients with CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week; 2) patients with CIN 3 who will undergo standard treatment with Transformation Zone Excision (EZT); 3) patients with negative cytology and HPV. Blood and cervicovaginal lavage will be collected for immunophenotypic analysis (flow cytometry), quantification of immunological mediators (Cytometric Bead Array) and evaluation of the microbiome (MiniION). The results obtained will be correlated with the clinical and pathological data of the patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
| Recruiting |
NCT05548933 -
Effects of Non-surgical Periodontal Therapy on Severe Periodontitis and Hyperlipidemia
|
||
| Active, not recruiting |
NCT03926572 -
Acute Decompensation of Pulmonary Hypertension
|
N/A | |
| Recruiting |
NCT05372159 -
Vanderbilt Memory and Aging Project
|
||
| Completed |
NCT03173586 -
Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women
|
N/A | |
| Completed |
NCT04554628 -
Early Prediction of Acute Kidney Injury Among Patients Admitted to Surgical ICU
|
N/A | |
| Terminated |
NCT03250312 -
The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers
|
N/A | |
| Recruiting |
NCT04666766 -
Detecting Traumatic Intracranial Hemorrhage With Microwaves and Biomarkers
|
N/A | |
| Completed |
NCT04573543 -
The Role of Immune Semaphorins in NAFLD
|
||
| Completed |
NCT03193671 -
Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
|
N/A | |
| Recruiting |
NCT06047132 -
PREDICTIVE ABILITY OF A PANEL OF BIOMARKERS IN SALIVA IN HEALTHY AND PERIODONTALLY AFFECTED SUBJECTS
|
||
| Completed |
NCT05361460 -
Patients Experiences of Early Postoperative Cognition
|
||
| Recruiting |
NCT05706194 -
Early Neuroprognostication After OHCA
|
||
| Recruiting |
NCT05138731 -
Metabolomics Profiling of Coronary Heart Disease
|
||
| Not yet recruiting |
NCT04563000 -
Impact of Vitamin C on Biomarkers of Neurologic Injury in Survivors of Cardiac Arrest
|
Phase 2 | |
| Completed |
NCT05138692 -
Biomarkers and Outcome 1 and 10-15 Years After Severe Traumatic Brain Injury
|
||
| Completed |
NCT02247999 -
Improving Cervical Cancer Screening Among HIV-Infected Women in India
|
||
| Active, not recruiting |
NCT02732301 -
Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers
|
||
| Not yet recruiting |
NCT03269019 -
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
|
N/A | |
| Recruiting |
NCT04062279 -
Predictors of Parkinson's Disease Progression
|